Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. (DNTH) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DNTH · as of Sep 30, 2025
Ownership Breakdown
149
Institutional Holders
▲ 45 vs Q2
$1.84B
Total Inst. Value
▲ $1.11B vs Q2
41.75M
Shares Outstanding
freeFloat 69.84%
46.84M
13F Shares Held
▲ 7.73M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DNTH largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 5.97M | 16.67% | 16.67% | $234.94B | Nov 13, 2025 | ▲ 1.43M |
FAIRMOUNT FUNDS MANAGEMENT LLC pharmaceutical preparations | 3.31M | 9.23% | 9.23% | $130.14B | Nov 14, 2025 | ▲ 600.0K |
AVIDITY PARTNERS MANAGEMENT LP pharmaceutical preparations | 3.20M | 8.94% | 8.94% | $126.08B | Nov 14, 2025 | ▲ 1.46M |
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 2.87M | 8.00% | 8.00% | $112.81B | Nov 14, 2025 | — held |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 2.58M | 7.20% | 7.20% | $101.43B | Nov 14, 2025 | ▲ 2.50M |
OCTAGON CAPITAL ADVISORS LP pharmaceutical preparations | 2.42M | 6.75% | 6.75% | $95.10B | Nov 14, 2025 | ▲ 75.0K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 2.04M | 5.70% | 5.70% | $80.35B | Nov 14, 2025 | ▲ 649.4K |
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 1.68M | 4.68% | 4.68% | $65.98B | Nov 17, 2025 | ▲ 175.0K |
VANGUARD GROUP INC pharmaceutical preparations | 1.64M | 4.58% | 4.58% | $64.62B | Nov 7, 2025 | ▲ 196.1K |
BLACKROCK, INC. pharmaceutical preparations | 1.34M | 3.74% | 3.74% | $52.73B | Nov 12, 2025 | ▼ 18.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+10.38M shares12
New Positions
first time holders11
Decreased
−4.61M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.77M
+10.38M / −4.61M
Net new holders
+24
12 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DNTH insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
11
Sell transactions
1.18
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Randhawa Simrat EVP, Head of R&D | Jun 1, 2026 | Sale | 5,428 | $89.72 | $487.0K | 25.1K | Form 4 ↗ |
Randhawa Simrat EVP, Head of R&D | Jun 1, 2026 | Sale | 16,943 | $90.72 | $1.54M | 8.2K | Form 4 ↗ |
Randhawa Simrat EVP, Head of R&D | Jun 1, 2026 | Sale | 4,159 | $91.37 | $380.0K | 4.0K | Form 4 ↗ |
Romano Steven J. director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Read Simon director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Lawton Alison Frances director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
McGeorge Anne director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
KANGO SUJAY director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Violin Jonathan director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Soteropoulos Paula director | May 21, 2026 | Award | 6,090 | $89.63 | $545.8K | 6.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Dianthus Therapeutics, Inc. (DNTH) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 30.16%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Dianthus Therapeutics, Inc. is FMR LLC, holding approximately 5.97 million shares — equal to 16.67% of outstanding shares — as of September 30, 2025.
A total of 149 institutional investors currently hold DNTH stock, with a combined institutional value of approximately $1.84 billion as of the most recent 13F filing period.
Frequently asked questions
DNTH ownershipDianthus Therapeutics, Inc. (DNTH) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is FMR LLC with a 16.67% stake. Company insiders hold 30.16%. Data sourced from SEC Form 13F as of September 30, 2025.